PUBLISHER: DelveInsight | PRODUCT CODE: 1074052
PUBLISHER: DelveInsight | PRODUCT CODE: 1074052
Glaucoma - Epidemiology Forecast - 2032
DelveInsight's 'Glaucoma-Epidemiology Forecast-2032' report delivers an in-depth understanding of the Glaucoma , historical and forecasted epidemiology as well as the Glaucoma trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Glaucoma Disease Understanding
According to the American Academy of Ophthalmology, glaucoma describes a group of conditions in which there is characteristic cupping of the optic disc with corresponding visual field defects due to retinal ganglion cell loss. It is a progressive condition and the most common cause of irreversible blindness worldwide. The two major categories of glaucoma are open-angle glaucoma and narrow-angle glaucoma/angle-closure glaucoma. The "angle" in both cases refers to the drainage angle inside the eye that controls the outflow of the watery fluid (aqueous) which is being produced inside the eye.
Open-angle glaucoma (OAG) is the most common form of the disease. The drainage angle formed by the cornea and iris remains open, but the trabecular meshwork is partially blocked. This causes pressure in the eye to increase gradually and damages the optic nerve. It happens so slowly that the patient may lose vision before they are even aware of a problem, while in the case of narrow-angle glaucoma, the structure inside the eye that allows fluid to drain normally from the eye (called the drainage angle) becomes restricted. Narrow drainage angles in the eye increase the risk of the drainage angle that gets blocked, resulting in a significant increase in eye pressure and risk of vision loss. If this occurs, narrow-angle glaucoma is usually called angle-closure glaucoma.
Glaucoma Epidemiology Perspective by DelveInsight
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalence of Glaucoma, Type-specific Diagnosed Prevalence of Glaucoma, Type-specific Diagnosed Prevalence of Open-Angle Glaucoma, Type-specific Diagnosed Prevalence of Secondary Open-Angle Glaucoma, Gender-specific Diagnosed Prevalence of Glaucoma, Age-specific Diagnosed Prevalence of Glaucoma scenario in the 7MM covering the United States, EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.
Glaucoma Detailed Epidemiology Segmentation
- The total diagnosed prevalent population of Glaucoma in the 7MM was 11,048,000 in 2021, which is expected to increase in the forecast period (2022-2032).
- Among the five European countries, Germany had the highest diagnosed prevalent population of Glaucoma with 1,115,113 cases, followed by Italy and France in 2021. On the other hand, Spain had the lowest.
- Japan had 3,387,932 diagnosed prevalent cases for Glaucoma in 2021.
- In 2021, in the United States, open-angle glaucoma was more prominent than closed angle with total cases of 3,119,031 cases of open angle glaucoma. Out of these total open-angle glaucoma cases, 2,807,128 cases were of primary open-angle glaucoma whereas secondary open-angle glaucoma had 311,903 cases in the United States in 2021.
- There were a total of 273,002 cases of steroid induced glaucoma in Japan in 2021. These cases are anticipated to decrease during the forecast period.
- Highest number of cases of glaucoma in the 7MM wre observed in the 40years and above age group with a total of 10,099,987cases in 2021. The least number of cases were observed in 2 to <18 years of age group. These cases are anticipated to increase during the forecast period.
"As per DelveInsight's analysis, a higher percentage of diagnosed prevalence was observed for females, in comparison to males, in all the 7MM countries. The highest proportion of Gluacoma cases was observed in 40 years and above age group in the 7MM. Among the major types of Glaucoma, i.e., open-angle and close-angle glaucoma, the former one accounts for a higher number of diagnosed Glaucoma cases".
Scope of the Report:
- The report covers the descriptive overview of Glaucoma, explaining its causes, symptoms, pathophysiology, and genetic basis.
- The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU-5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
- The report assesses the disease risk and burden and highlights the unmet needs of Glaucoma.
- The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
- The report provides the segmentation of the disease epidemiology for 7MM by Total Diagnosed Prevalence of Glaucoma, Type-specific Diagnosed Prevalent Population of Glaucoma, Gender-specific Diagnosed Prevalence of Glaucoma, Age-specific Diagnosed Prevalence of Glaucoma, Type-specific Diagnosed Prevalence of Open-Angle Glaucoma.
Report Highlights:
- 11-Year Forecast of Glaucoma
- 7MM Coverage
- Total Diagnosed Prevalence of Glaucoma
- Type-specific Diagnosed Prevalence of Glaucoma
- Type-specific Diagnosed Prevalence of Open-Angle Glaucoma
- Type-specific Diagnosed Prevalence of Secondary Open-Angle Glaucoma
- Gender-specific Diagnosed Prevalence of Glaucoma
- Age-specific Diagnosed Prevalence of Glaucoma
Key Questions Answered
- What are the disease risk, and burden of Glaucoma ?
- What is the historical Glaucoma patient pool in the United States, EU-5 (Germany, France, Italy, Spain, and the UK), and Japan?
- What would be the forecasted patient pool of Glaucoma at the 7MM level?
- What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Glaucoma ?
- Out of the above-mentioned countries, which country would have the highest prevalent population of Glaucoma during the forecast period (2022-2032)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?
Reasons to buy:
The Glaucoma report will allow the user to -
- Develop business strategies by understanding the trends shaping and driving the 7MM Glaucoma epidemiology forecast.
- The Glaucoma epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
- The Glaucoma epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.
Key Assessments
- Patient Segmentation
- Disease Risk and Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
Geographies Covered
- The United States
- EU-5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2019-2032.
Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary of Glaucoma
4. Disease Background and Overview
- 4.1. Introduction
- 4.2. Classification of Glaucoma
- 4.2.1. Classification of Open-Angle Glaucoma (OAG)
- 4.2.1.1. Primary Open-Angle Glaucoma (POAG)
- 4.2.1.2. Secondary Open-Angle Glaucoma
- 4.2.2. Classification of Close-Angle Glaucoma/Angle-closure glaucoma (ACG)
- 4.2.1. Classification of Open-Angle Glaucoma (OAG)
- 4.3. Signs and Symptoms of Glaucoma
- 4.3.1. Signs and Symptoms of Open-Angle Glaucoma
- 4.3.2. Signs and Symptoms of Closed-angle Glaucoma
- 4.4. Genes Involved in Glaucoma
- 4.4.1. Primary Open Angle Glaucoma
- 4.4.2. Primary Closed Angle Glaucoma (PACG)
- 4.5. Diagnosis
- 4.5.1. Diagnosis of Glaucoma
- 4.5.2. Diagnostic criteria of Angle Closure Glaucoma
- 4.5.3. Differential Diagnosis of Glaucoma
- 4.5.4. Diagnostic Algorithm for Glaucoma
- 4.5.5. Diagnosis of Juvenile Open Angle Glaucoma (JOAG)
- 4.5.6. Diagnosis of Steroid Induced Glaucoma (SIG)
- 4.5.7. Primary Glaucoma Preferred Practice Pattern guidelines
5. Epidemiology and Patient Population
- 5.1. Key Findings
- 5.2. Epidemiology Methodology
- 5.3. Total Diagnosed Prevalence of Glaucoma in the 7MM
- 5.4. Assumptions and Rationales: 7MM
- 5.5. The United States
- 5.5.1. Total Diagnosed Prevalence of Glaucoma in the United States
- 5.5.2. Type-specific Diagnosed Prevalence of Glaucoma in the United States
- 5.5.3. Type-specific Diagnosed Prevalence of Open-Angle Glaucoma (OAG) in the United States
- 5.5.4. Type-specific Diagnosed Prevalence of Secondary Open-Angle Glaucoma in the United States
- 5.5.5. Gender-specific Diagnosed Prevalence of Glaucoma in the United States
- 5.5.6. Age-specific Diagnosed Prevalence of Glaucoma in the United States
- 5.6. EU5
- 5.6.1. Total Diagnosed Prevalence of Glaucoma in the EU-5
- 5.6.2. Type-specific Diagnosed Prevalence of Glaucoma in EU-5
- 5.6.3. Type-specific Diagnosed Prevalence of Open angle Glaucoma in EU-5
- 5.6.4. Type-specific Diagnosed Prevalence of Secondary Open-Angle Glaucoma in EU-5
- 5.6.5. Gender-specific Diagnosed Prevalence of Glaucoma in EU-5
- 5.6.6. Age-specific Diagnosed Prevalence of Glaucoma in EU-5
- 5.7. Japan
- 5.7.1. Total Diagnosed Prevalence of Glaucoma in Japan
- 5.7.2. Type-specific Diagnosed Prevalence of Glaucoma in Japan
- 5.7.3. Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan
- 5.7.4. Type-Specific Diagnosed Prevalence of Secondary Open-Angle Glaucoma in Japan
- 5.7.5. Gender-specific Diagnosed Prevalence of Glaucoma in Japan
- 5.7.6. Age-specific Diagnosed Prevalence of Glaucoma in Japan
6. Patient Journey
7. KOL views
8. Appendix
- 8.1. Report Methodology
- 8.2. Bibliography
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
List of Tables
- Table 1: Summary of Glaucoma Epidemiology, and Key Events (2019-2032)
- Table 2: Two Classes of Primary Open-Angle Glaucoma (POAG) Mutations
- Table 3: Genes associated with the risk of POAG
- Table 4 : Genes identified in linkage or association with PACG
- Table 5: Clinical findings that define patients seen with Angle-Closure disease
- Table 6: Differential Diagnosis for Glaucoma
- Table 7: The definitions and levels of evidence to rate individual studies
- Table 8: Total Diagnosed Prevalence of Glaucoma in the 7MM, in '00 (2019-2032)
- Table 9: Total Diagnosed Prevalence of Glaucoma in the United State, in '00 (2019-2032)
- Table 10: Type-specific Diagnosed Prevalence of Glaucoma in the US, in '00 (2019-2032)
- Table 11: Type-specific Diagnosed Prevalence of OAG in the United States, in '00 (2019-2032)
- Table 12: Type-specific Diagnosed Prevalence of Secondary Open-Angle Glaucoma in the United States, in '00 (2019-2032)
- Table 13: Gender-specific Diagnosed Prevalence of Glaucoma in the US, in '00 (2019-2032)
- Table 14: Age-Specific Diagnosed Prevalence of Glaucoma in the United States, in '00 (2019-2032)
- Table 15: Total Diagnosed Prevalence of Glaucoma in EU-5, in '00 (2019-2032)
- Table 16: Type-specific Diagnosed Prevalence of Glaucoma in EU-5, in '00 (2019-2032)
- Table 17: Type-specific Diagnosed Prevalence of OAG in EU-5, in '00 (2019-2032)
- Table 18: Type-specific Diagnosed Prevalence of Secondary Open-Angle Glaucoma in EU-5, in '00 (2019-2032)
- Table 19: Gender-specific Diagnosed Prevalence of Glaucoma in EU-5, in '00 (2019-2032)
- Table 20: Age-Specific Diagnosed Prevalence of Glaucoma in EU-5, in '00 (2019-2032)
- Table 21: Total Diagnosed Prevalence of Glaucoma in Japan, in '00 (2019-2032)
- Table 22: Type-specific Diagnosed Prevalence of Glaucoma, in Japan in '00 (2019-2032)
- Table 23: Type-specific Diagnosed Prevalence of OAG in Japan, in '00 (2019-2032)
- Table 24: Type-specific Diagnosed Prevalence of Secondary OAG in Japan, in '00 (2019-2032)
- Table 25: Gender-specific Diagnosed Prevalence of Glaucoma in Japan, in '00 (2019-2032)
- Table 36: Age-Specific Diagnosed Prevalence of Glaucoma in Japan, in '00 (2019-2032)
List of Figures
- Figure 1: Classification of Glaucoma
- Figure 2: Classification of Open-Angle Glaucoma
- Figure 3: Risk Factors Associated with POAG
- Figure 4: Glaucoma classification and subtypes.
- Figure 5: Symptoms of Open-Angle Glaucoma
- Figure 6: Symptoms of Closed-angle Glaucoma
- Figure 7 : Proposed pathways for normal secretion of myocilin into the aqueous humor and for secretion reduced by an MYOC mutation
- Figure 8: Diagnosis of Glaucoma
- Figure 9: Total Diagnosed Prevalence of Glaucoma in the 7MM (2019-2032)
- Figure 10: Total Diagnosed Prevalence of Glaucoma in the United States (2019-2032)
- Figure 11: Type-specific Diagnosed Prevalence of Glaucoma in the US (2019-2032)
- Figure 12: Type-specific Diagnosed Prevalence of OAG in the United States (2019-2032)
- Figure 13: Type-specific Diagnosed Prevalence of Secondary Open-Angle Glaucoma in the United States (2019-2032)
- Figure 14: Gender-specific Diagnosed Prevalence of Glaucoma in the US (2019-2032)
- Figure 15 Age-Specific Diagnosed Prevalence of Glaucoma in the United States (2019-2032)
- Figure 16: Total Diagnosed Prevalence of Glaucoma in the EU-5 (2019-2032)
- Figure 17: Type-specific Diagnosed Prevalence of Glaucoma in EU-5 (2019-2032)
- Figure 18: Type-specific Diagnosed Prevalence of OAG in EU-5 (2019-2032)
- Figure 19: Type-specific Diagnosed Prevalence of secondary Open-Angle Glaucoma in EU-5 (2019-2032)
- Figure 20: Gender-specific Diagnosed Prevalence of Glaucoma in EU-5 (2019-2032)
- Figure 21 Age-specific Diagnosed Prevalence of Glaucoma in EU-5 (2019-2032)
- Figure 22: Total Diagnosed Prevalence of Glaucoma in Japan (2019-2032)
- Figure 23: Type-specific Diagnosed Prevalence of Glaucoma in Japan (2019-2032)
- Figure 24: Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan (2019-2032)
- Figure 25: Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan (2019-2032)
- Figure 26: Gender-specific Diagnosed Prevalence of Glaucoma in Japan (2019-2032)
- Figure 27: Age-specific Diagnosed Prevalence of Glaucoma in Japan (2019-2032)
